Index

Titles of publications appear in italics.

Abernethy, M. 132
academic research, see universities, research
acceptable level of health 21–2
acquisitions, biotechnology sector 139–40
ageing population, and health service demand 34–6
agglomeration, see clusters
Albino, V. 185
Allio, M.K. 163
ambulatory health provision 28–9
Anderson, R. 22
Anglo American, strategic decision-making 51
anthrax, and strategic decision-making 51, 52
antidepressants 83
hedonic pricing model 87–8
therapeutic effectiveness measurement 85
antihistamines 83
hedonic pricing model 91
antimicrobials 83–4
hedonic pricing model 89–90
therapeutic effectiveness measurement 85
Arrow, K. 128
Arthur, J. 132
Audretsch, D.B. 190
Australia, university research policy 116–19
Barrett, P. 106, 107
Bayh–Dole Act 143, 258–9
benchmarking hospital costs, UK 150–65
Bianchi, P. 63, 176
biomedical machines, innovative systems, Italy 245
biomedical research 135
biotech industry 136–40
capital risk investment, Europe 261–3
clusters 189–96, 208–17
San Diego 227–8
intangible assets 140–41, 177–81, 190–95
startups 192–4, 208–9
university links 209–10, 213–16
see also pharmaceutical industry
Biovalley, biotech firm clusters 194–5
Bothwell, M. 177
Bottazzi, G. 139
branded drugs, pricing 81–2, 85–6
antidepressants 87
calcium channel blockers 88–9
Britain, see United Kingdom
Buigues, P. 125
Burton-Jones, A. 183
Caddy, I. 106
calcium channel blockers (CCBs) 83
hedonic pricing model 88–9
California, regional spillovers 226–9
Camp, R.C. 153
Canada, pharmaceutical prices 37
capital costs, impact on benchmarking 161
capital risk fund shortage, France 261–3
casemix, impact on hospital benchmarking 161
centre-based approach to collaborative research 113–14
clusters 206–17, 224–6, 234–5
biotechnology industry 189–96, 208–17, 227–8
high-tech
France 260–76
Italy 235–49
and intangible assets 182–96
Coase, R. 50
codified knowledge 184
collaborative agreements, biotechnology 138–9

collaborative research, see research alliances

collective learning, biotech companies 191

communication, Genopole 268

collaborative agreements, 

biotechnology 138–9

collaborative research, see research alliances

commercialization, university research 116–19; see also research alliances

communication, Genopole 268

competition

health plans, USA 24–5

international, health systems 37

competition–cooperation 72–3

complementarity 130–31, 134, 141–3; see also intangible assets

Consorzio Ferrara Ricerche (CFR) 120
corporatization of research, see research alliances

cost containment policies 22–5, 60–61, 62–5
costs

drugs, see pharmaceuticals, pricing

medical R&D 33
county manager view of firm location 210

Cowling, K. 50, 53

Danby, M.R. 209
decision-making, strategic, and economic impact 50–53
demand, health services 34–6
demand-related horizontal interactions, clusters 225

Desrochers, P. 184
development of economies 48–9

Di Tommaso, M.R. 46, 47, 171
direct business funding, collaborative research 114
direct intellectual capital methods (DIC) 173
drugs, see pharmaceuticals

Duffy, J. 105

East Asia, university research 109
economic development and health status 10

of localities 48–9
economic efficiency, and industrial promotion 4
economic impact

and strategic decision-making 50–53

University of California research alliances 227–9

Economic Report of the President, US 6

economics and intangible assets 127–31

economies of agglomeration assets 208; see also clusters

Edvinsson, L. 108, 174

efficiency, health supply 38–9

employment

Futuroscope 272

Genopole 267

health sector 19–21

impact, UC San Diego research alliances 228

Enthoven, A. 65

entrepreneurial view of firm location 210

Epple, D. 82

Europe

biotech clusters 193–5

health policies 59–74

pharmaceutical industry 135–40

R&D funding 259

technology policy 258, 259

university research 109

Eustace, C. 174

expenditure, see health expenditure

export potential of health industry 36–7

Feldman, M.P. 185

Ferrara

economic development 48–9

University research activities 120–22

Ferrera, M. 71–2

finance

Futuroscope 273

Genopole 267, 269

health care 9, 29–30, 55

see also health expenditure

intangible assets 187

NHS, Britain 55

organisations 29–30

university research 110, 114–15, 116

firm’s value, intangible determinants 133–4
foundation hospitals, Britain 55
France
capital risk fund shortage 261–3
health research 142
high-tech clusters 260, 265–76
research problems 261–4
taxation 263–4
French Society Against Myopathies, The 265–6
funding, see finance
Future Management of Crown Copyright, The 107–8
Futuroscope 260, 271–5
G-7 countries
ageing population 35–6
employment, health sector 19–21
expenditure, health sector 18–19, 22–9, 30–33
Gallagher, M. 117
Garcia-Ayuso, M. 132
generation of drugs, effect on pricing 86, 95
antidepressants 87
glaucoma treatments 92
generic drugs, pricing 81–2, 85–6
antidepressants 87
calcium channel blockers 88–9
GenHomme 270
Genoplante 270
Genopole 260, 265–71
geographical proximity, see clusters
Geroski, P. 127
glaucoma treatments, see ophthalmic solutions for glaucoma
GlaxoSmithKline, strategic decision-making 51
globalisation of health issues 56
Goldsmith, J. 32
governance, health industry 55–6
government
funding, see public funding
policies, new technologies 12
strategic decision-making 51–2
Great Britain, see United Kingdom
Guthrie, J. 118

Haig, R. M. 182
Hall, S. J. 182
Health Behavior Model 22
health care funding 9, 29–30, 55
health care providers 7, 9
Health Industry Model 25, 27–9
health care resource groups (HRGs) 151
health expenditure
G-7 countries 18–19, 22–9, 30–33
hospitals, benchmarking 150–65
management 6–7, 63–73
see also health care funding
health industry 6–11, 46
costs, see health expenditure
decision-making 53–5
export potential 36–7
impact on economics 10–11, 47–53
intangible assets 177–81
structure 7–9
health industry branches, MNEs, Italy 238–40
and local systems 240–46
Health Industry Model 7, 25–33, 46, 47, 207
policy implications 33–9
health insurance
role in health process 65–6
USA 29–30
health maintenance organisations and drug prices 79–80, 94
Health Model 7, 21–5
policy implication 33–9
health product manufacturers 9, 30–33; see also pharmaceutical industry
health service demand 34–6
Europe 62–3
health systems
international competition 37
strategies, Europe 60–74
hedonic theory, drug pricing 80–97
Henderson, R. 135, 138
HIBs, see health industry branches
high-tech clusters 225
France 260–76
Italy 235–49
see also biotech industry, clusters
high-technology industry promotion 3–6
higher education institutes, see universities
HIM, see Health Industry Model
HM, see Health Model
HMOs (health maintenance organisations) and drug prices 79–80, 94
Holloway, J. 153
horizontal interactions, clusters 225
hospitals, 25, 27–8
costs, benchmarking 150–65
as election issue 52
foundation 55
HRGs (health care resource groups) 151
human capital as intangible asset 130–31
Hutton, W. 54
Independent Kidderminster Hospital and Health Concern Party 52
industrial district development 233–4;
see also clusters
industrial health cluster effect 246
industrial policy, high-tech industry 3–6
industrial promotion 3–6
industry, research collaboration with universities, see research alliances
information 183–4
innovation
impact of benchmarking 165
as intangible asset 127–8
law, France 264–5
pharmaceutical, impact of pricing 77–8
see also research and development
innovative systems and health industry, Italy 245–6
insurance, see health insurance
intangible assets 125–43, 171–96
classification 174–7
and clustering 182–96
health industry 134–41, 177–81
intellectual capital 103–8, 131–2
intellectual property (IP) 103–8
international trade, health industry 37
intervention policies, Europe 60–73
investment, research and development 32–3, 172
Italy
multinational enterprises and high-tech clusters 235–50
university research policy 119–22
job creation
Futuroscope 272
Genopole 267
Kidderminster Hospital, as election issue 52
knowledge 183–4
as intangible asset 128–9
management 105–8
knowledge capital 132
indexes, health companies 177–9
Labory, S. 176
‘ladder of success’ benchmark 155–7
LeGrand, J. 61
Lev, B. 132, 174, 176, 177, 184
Levin, R. 129
‘List of shame to feature NHS Trust costs’ (Financial Times) 152
local systems, Italy 241–4
and MNEs 233–50
localisation, see clusters
Lowendahl, B. 174, 188
Maciocco, G. 66
macroeconomic intervention, Europe 60–61
managed competition policies 65–8
managed cooperation model 68–70
manufacturers, health products 9, 30–33; see also pharmaceutical industry
manufacturing local systems (MLS) 237
market capitalization methods (MCM) 173
market factors and drug pricing 79, 85–6
market failures
ideas market 128
rationale for industrial policy 4
market incentives to improve efficiency 38–9
market, international, health systems 37
market-to-book ratio 178–9
marketing, pharmaceuticals 33, 78–9, 180–81
Marshall, A. 224
Martin, M. 104
measurement, intangible assets 173–4
medical equipment 31–3
medical services, international trade 37
medical training and strategic decision-making 51–2
mergers, biotechnology sector 139–40
meta-economic objectives, rationale for industrial promotion 4, 6
microeconomic intervention 61, 65–8
Milgrom, P. 130
MMR vaccine, parental decision-making 53
MNEs, see multinational enterprises
Monsanto Co., and Washington University 221–2
Mossialos, E. 61
multinational enterprises (MNEs) and high-tech clusters, Italy 235–50
and industrial district development 233–4
National Health Service, Britain
managed competition model 66
strategic decision-making 54–5
national reference cost index (NRCI) 151, 155–65
national reference costing exercise (NRCE) 151–65
National Schedule of Reference Costs (NSRC) 155–65
Naturascope project 274–5
Neumann, R. 118
new biotechnology companies (NBCs) 190–91
NHS, see National Health Service, Britain
non-manufacturing local systems (NMLS) 237
NRCE (national reference costing exercise) 151–65
NRCI (national reference cost index) 151, 155–65
NSRC (National Schedule of Reference Costs) 155–65
ophthalmic solutions for glaucoma 84
hedonic pricing model 91–2
organization as intangible asset 129–30
outpatient surgery 29
Paci, M. 71–2
Pammolli, F. 191
Paris, biotech cluster 194
paternalistic reasons for industrial promotion 4, 6
patient information 33
pharmaceutical industry
intangible assets 134–41, 177–81
locations 210
MNEs and local systems, Italy 241
pharmaceuticals
development costs 78–9
expenditure 30–31
investment 32–3
marketing 33
pricing 37, 51, 52, 77–97
pharmacies, and drug prices 79–80, 84, 94
physicians, ambulatory 28–9
Pierson, P. 60–61
Polanyi, K. 71
Porter, M. 188
pre-competitive approach to collaborative research 113
pricing of pharmaceuticals 37, 51, 52, 77–97
programming by integrated setting 68–70
property strategy
Futuroscope 272
Genopole 266–7
public
expectations of health services 36
opinion of British NHS 54–5
public funding
health care 22–4
university research 110
public–private partnerships, research 112–15
reciprocity and welfare systems 71
regional clusters, see clusters
regional impact analysis, research alliances 222–3
regional spillovers, California 226–9
regional technology poles, Europe 260–61; see also high-tech clusters
Reilly, R. 176
relational capital 132
research alliances 112–15, 220–31
Index

Australia 116–19
biotech industry 138–9
Italy 119–22
University of California 226–9
research and development
biotechnologies 32–3, 136–40
France 261–76
investment 32–3, 172
medical equipment 32–3
research, university
industry partnerships, see research alliances
OECD 108–12
USA 212–13
return on assets methods (ROA) 173
Riccaboni, M. 191
risk, and intangible assets 186–7
Roberts, J. 130
San Diego, biotech clustering
227–8
Schiuma, G. 185
Schweitzer, S.O. 46, 47, 171
science parks 260
scientific research, see research
scientists, role in biotech companies
192–3
scorecard methods 173
Sen, A. 22
size, health sector 18–21
social regulation systems 70–73
specialist hospitals, benchmarking
problems 160–62
spending, see health expenditure
spillovers
health industry 38
innovation 128–9
research alliances 220–31
Stephan, P.E. 190
Stewart, T.A. 172
Stiglitz, J. 56
Storey, D.J. 260
Storper, M. 187
strategic decision-making
and health systems 50–56
and industry promotion 4, 6
structural capital 131–2
Sugden, R. 50, 53
supply-related vertical interactions,
clusters 225
tacit knowledge 183–4
Tambourin, P. 266
taxation, France, impact on companies
263–4
Taylor, R. 52
technology poles, regional 260–61; see also high-tech clusters
telemedicine 37
territorialization 187
Thomas, L. 141
Thomson, G. 132
trade, international, medical services
37
training, medical, and strategic
decision-making 51–2
uncertainty and intangible assets 186–7
United Kingdom
biotech firm clusters 194
hospital costs benchmarking 150–65
intellectual property management
107–8
managed competition model 66
universities
and biotech firms 209–10, 213–16
California, economic impact of
research 226–9
Ferrara, research activities 120–22
and Genopole 268–9
and knowledge management 103–22
research 108–22
collaboration with industry, see
research alliances
university entrepreneurial approach to
collaborative research 114
USA
biotech clusters 192–3
biotechnology industry 136–40
drug pricing 37, 78–96
health care spending 24–5
health insurance 29–30
health system 207
hospitals 27–8
pharmaceutical industry 135
research model 264
technology policy 258–9
venture capital
and biotech clusters, US 193
and intangible assets 187
vertical interactions, clusters 225
Viagra, controlled availability 51
Washington University, collaboration with Monsanto 221–2
welfare regulation systems 70–73

Westhead, P. 260
Wolfram Cox, J. 153
Zeitlin, M. 50, 51
Zucker, L.G. 209